Protocol Ledger

NCT05295459 · Phase III · COMPLETED

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

Interventional Phase III clinical trial protocol NCT05295459 sponsored by Lyra Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-13 Enrollment: 182 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05295459
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)182 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05295459
Protocol FieldVerified Registry Value
NCT IdentifierNCT05295459
Consolidated Lead SponsorLyra Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment182 participants (ACTUAL)
Registered Start Date2022-05-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI